Old Web
English
Sign In
Acemap
>
authorDetail
>
Rea Delphine
Rea Delphine
Immunology
Medicine
Nilotinib
Discontinuation
Imatinib
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd
2012
Blood
Rea Delphine
Jean-François Gautier
Massimo Breccia
Giuseppe Saglio
Timothy P. Hughes
Hagop M. Kantarjian
Charisse Kemp
Haitao Gao
Carmen Piccolo
Richard A. Larson
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (18)
Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)
2011
Blood
Hyacinthe Johnson Ansah
Joelle Guilhot
Philippe Rousselot
Rea Delphine
Françoise Rigal-Huguet
Franck E. Nicolini
Anne Vekhoff
Agnès Guerci-Bresler
Michele Schoenwald
Eric Jourdan
Laurence Legros
Valérie Coiteux
François-Xavier Mahon
Claude Preudhomme
François Guilhot
Show All
Source
Cite
Save
Citations (1)
Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia
2010
Blood
Deau Benedicte
Bachy Emmanuel
Raus Nicole
Nicolini Franck-emmanuel
Rea Delphine
Reman Oumedaly
Maillard Natacha
Shanti Ame
Fegueux Nathalie
Coiteux Valerie
Gardembas Martine
Charbonnier Aude
Huyn Anne
Cahn Jean Yves
Buzyn Agnes
Show All
Source
Cite
Save
Citations (1)
1